Scope
The ACG guideline addresses adults with active Helicobacter pylori infection, emphasizing reliable eradication, antibiotic stewardship and confirmation of cure. Its recommendations prioritize North American evidence and distinguish first treatment from persistent infection after previous therapy. Treatment selection depends on previous regimens, antibiotic exposure, allergy and available susceptibility results.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Connect testing to treatment and cancer prevention
- Offer effective eradication treatment when an appropriate test confirms active infection, and arrange a subsequent test of cure. Testing and treatment are linked decisions; this guidance concerns infection confirmed by a nonserological test. [1]
- For uninvestigated dyspepsia, test-and-treat is reasonable below age 60 only without alarm features or another endoscopy indication. Alarm features include vomiting, gastrointestinal bleeding, unexplained iron deficiency and weight loss; cancer-risk context may justify a lower age threshold or endoscopy. [1]
- Other testing groups include adult household contacts of people positive by nonserological testing, unexplained iron deficiency, immune thrombocytopenia, current or previous peptic ulcer disease, chronic NSAID use and initiation of daily aspirin. [1]
- Eradicate infection in gastric atrophy, intestinal metaplasia, dysplasia and resected early gastric cancer. Eradication does not remove the need for surveillance in high-risk premalignant disease; this summary does not define surveillance intervals. [1]
Choose initial therapy without ignoring resistance
- For treatment-naive adults with unknown antibiotic susceptibility, optimized bismuth quadruple therapy for 14 days is preferred. The first-line BQT recommendation is strong, with moderate-quality evidence. [1]
- BQT combines a bismuth salt, metronidazole or another specified nitroimidazole, tetracycline and a PPI. Do not casually substitute doxycycline for tetracycline or reduce the recommended metronidazole exposure; these modifications are associated with poorer eradication. [1]
- Rifabutin triple therapy—PPI, rifabutin and amoxicillin—is a suggested first-line alternative, with low-quality evidence. A 14-day course is an empirical alternative only when there is no penicillin allergy; this summary does not supply a complete rifabutin dosing prescription. [1]
- A potassium-competitive acid blocker plus amoxicillin is another suggested initial option, with moderate-quality evidence. The guideline identifies a 14-day PCAB dual regimen as an empirical alternative in people without penicillin allergy. [1]
- Avoid clarithromycin- or levofloxacin-containing regimens without demonstrated susceptibility as the general stewardship rule. Do not select empirical clarithromycin or levofloxacin salvage therapy merely because another course failed. [1]
- The narrow first-line exception is unknown susceptibility, no prior macrolide exposure, no penicillin allergy and no other available first-line option: then 14-day PCAB–clarithromycin triple therapy is preferred over PPI–clarithromycin triple therapy. This is a conditional comparison, not routine empirical first-line treatment. [1]
- Concomitant PPI, clarithromycin, amoxicillin and metronidazole therapy is not suggested over BQT for treatment-naive patients. The recommendation is conditional with low-quality evidence. [1]
- With true penicillin allergy, optimized BQT is the suitable option among the recommended first-line and salvage regimens. If BQT is unsuitable and allergy is suspected, refer for confirmation and possible desensitisation instead of assuming every penicillin-allergy label is established. [1]
Match rescue treatment to previous exposure
- For persistent infection without prior optimized BQT, use the suggested 14-day optimized BQT pathway, including after failed PPI–clarithromycin triple therapy. BQT is preferred over quinolone rescue when optimized BQT has not yet been used. [1]
- If an earlier failed BQT course was not optimized, repeating it with correction of duration, metronidazole exposure, tetracycline choice and PPI dosing is acceptable. Check the actual prior prescription and adherence before labeling optimized BQT as failed. [1]
- After prior optimized BQT, rifabutin triple therapy for 14 days is a suggested rescue alternative. Its amoxicillin component makes true penicillin allergy relevant; persistent infection after these options calls for susceptibility-guided planning. [1]
- Levofloxacin triple rescue is suggested only for a known susceptible strain when optimized BQT or rifabutin therapy has already been used or is unavailable. Account for fluoroquinolone safety warnings. Clarithromycin triple rescue likewise requires demonstrated clarithromycin sensitivity. [1]
- Use susceptibility testing when therapy choice remains unclear after reviewing previous eradication courses, broader antibiotic exposure and documented penicillin allergy. Evidence is insufficient to recommend high-dose PPI or PCAB dual therapy routinely as salvage in North America. [1]
Confirm eradication rather than relying on symptoms
- Check cure in every treated patient with urea breath, stool antigen or a suitable biopsy-based test at least 4 weeks after treatment finishes. Symptom improvement does not establish eradication; serology cannot establish post-treatment cure. [1]
- Before breath or stool testing, stop PPIs for 2 weeks and avoid bismuth and antibiotics for at least 4 weeks. Standard-dose H2 blockers or antacids do not impair accuracy. Similar PCAB effects are plausible but inadequately studied; recent suppressive treatment also reduces biopsy-test sensitivity. [1]
- Support adherence by explaining why eradication matters and the adverse effects patients may encounter. Probiotic add-on treatment has insufficient evidence for improved eradication efficacy or tolerability; it is not established routine therapy in this guideline. [1]
Limitations and use
- This is a selected adult treatment summary based on the full article narrative. It does not reproduce the complete regimen tables, drug interactions, contraindications or individual product doses; confirm the exact formulation and prescribing instructions before use.
- The guideline prioritizes North American evidence. Local resistance, drug availability, product authorization and patient factors must inform application in India; it is not a paediatric or pregnancy treatment protocol.
- The source acknowledges a narrow treatment-naive exception when clarithromycin susceptibility is unavailable and no alternative first-line option exists. This exception does not justify empirical clarithromycin salvage treatment.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Helicobacter pylori Infection
Selected recommendation material consulted
Publication details
- Issuing organisation
- ACG
- Resource type
- Clinical guideline · House clinical summary
Earlier House summaries: helicobacter pylori infection acg
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.